来自官方财务报表的收入、利润与现金流历史。
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $614M | $507M | $383M | $315M | $283M | $294M | $225M | $237M | $181M | $159M | $114M | $72M | $46M | $21M | $2M |
| 毛利 | $485M | $393M | $289M | $239M | $214M | $227M | $133M | $198M | $156M | $138M | $98M | $59M | $34M | $18M | $1M |
| 毛利率% | 79.0% | 77.5% | 75.5% | 76.0% | 75.6% | 77.3% | 59.2% | 83.7% | 86.2% | 86.8% | 85.9% | 81.9% | 75.0% | 87.9% | 31.9% |
| 营业利润（EBIT） | ($80M) | ($87M) | ($122M) | ($129M) | ($82M) | ($33M) | ($124M) | ($50M) | ($13M) | ($2M) | $4M | ($10M) | ($13M) | ($14M) | ($22M) |
| 营业利润率% | -13.0% | -17.1% | -31.9% | -40.9% | -29.1% | -11.2% | -54.9% | -21.2% | -7.2% | -1.4% | 3.7% | -14.4% | -28.9% | -67.8% | -909.8% |
| 净利 | ($188M) | ($188M) | ($146M) | ($135M) | ($99M) | ($50M) | ($120M) | $15M | ($13M) | $0M | $5M | ($37M) | ($12M) | ($13M) | ($19M) |
| 净利润率 % | -30.6% | -37.0% | -38.2% | -42.8% | -35.1% | -16.9% | -53.5% | 6.5% | -7.1% | -0.1% | 4.0% | -51.9% | -26.6% | -60.3% | -795.8% |
| EBITDA | ($152M) | ($146M) | ($96M) | ($82M) | ($49M) | ($1M) | ($84M) | ($38M) | ($7M) | $5M | $9M | ($33M) | ($9M) | ($13M) | ($21M) |
| 每股收益（EPS） | $-3.25 | $-3.28 | $-2.77 | $-2.78 | $-2.09 | $-1.07 | $-2.70 | $0.37 | $-0.37 | $-0.00 | $0.12 | $-2.13 | $-0.49 | $-0.51 | $-9.73 |
| 已发行股数 (M) | 58M | 57M | 53M | 48M | 47M | 46M | 44M | 41M | 35M | 34M | 36M | 17M | 25M | — | 2M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 GKOS 交互式查看器。 /companies/us/GKOS
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms